BioCryst/$BCRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioCryst
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Ticker
$BCRX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
580
ISIN
US09058V1035
Website
BioCryst Metrics
BasicAdvanced
$1.9B
-
-$0.26
1.07
-
Price and volume
Market cap
$1.9B
Beta
1.07
52-week high
$11.31
52-week low
$6.02
Average daily volume
3.5M
Financial strength
Current ratio
2.931
Quick ratio
2.778
Long term debt to equity
-175.276
Total debt to equity
-176.793
Interest coverage (TTM)
0.35%
Profitability
EBITDA (TTM)
37.473
Gross margin (TTM)
64.25%
Net profit margin (TTM)
-10.62%
Operating margin (TTM)
6.84%
Effective tax rate (TTM)
-4.47%
Revenue per employee (TTM)
$870,000
Management effectiveness
Return on assets (TTM)
4.54%
Return on equity (TTM)
11.52%
Valuation
Price to revenue (TTM)
3.658
Price to book
-4.11
Price to tangible book (TTM)
-3.89
Price to free cash flow (TTM)
-68.504
Free cash flow yield (TTM)
-1.46%
Free cash flow per share (TTM)
-12.96%
Growth
Revenue change (TTM)
41.67%
Earnings per share change (TTM)
-75.60%
3-year revenue growth (CAGR)
38.86%
10-year revenue growth (CAGR)
40.35%
3-year earnings per share growth (CAGR)
-37.67%
10-year earnings per share growth (CAGR)
-9.67%
What the Analysts think about BioCryst
Analyst ratings (Buy, Hold, Sell) for BioCryst stock.
Bulls say / Bears say
BioCryst Pharmaceuticals reported a 52.7% year-over-year increase in first-quarter sales, reaching $145.50 million, surpassing consensus estimates of $126.87 million. (Benzinga)
The company's flagship product, ORLADEYO, has demonstrated significant and sustained reductions in hereditary angioedema attack rates in adolescents and severe cases, with real-world evidence supporting its efficacy. (GlobeNewswire)
Analysts have set an average 12-month price target of $17.43 for BCRX, indicating a potential upside of approximately 68% from the current price. (Wallstrank)
Despite strong revenue growth, BioCryst reported a net loss of $26.80 million in Q1 2025, highlighting ongoing profitability challenges. (Google Finance)
The company's total liabilities of $966.35 million exceed its total assets of $490.42 million, raising concerns about its financial leverage and balance sheet health. (Google Finance)
BioCryst's current Price-to-Sales (P/S) ratio of 3.7x is slightly above its estimated fair P/S ratio of 3.6x, suggesting the stock may be slightly overvalued relative to its sales. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
BioCryst Financial Performance
Revenues and expenses
BioCryst Earnings Performance
Company profitability
BioCryst News
AllArticlesVideos
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit
GlobeNewsWire·2 days ago
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
GlobeNewsWire·4 days ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioCryst stock?
BioCryst (BCRX) has a market cap of $1.9B as of July 11, 2025.
What is the P/E ratio for BioCryst stock?
The price to earnings (P/E) ratio for BioCryst (BCRX) stock is 0 as of July 11, 2025.
Does BioCryst stock pay dividends?
No, BioCryst (BCRX) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next BioCryst dividend payment date?
BioCryst (BCRX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioCryst?
BioCryst (BCRX) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.